Current adjuvant treatment modalities for gastric cancer: From history to the future

Table 1 Randomized trials of chemotherapy for resected gastric cancer, published after 2000s

Ref.	Regimen	LN (+) % (chemo)	T3-T4 % (chemo)	No. of patients	D2 % (chemo)	% 5-yr survival	P value
Neoadjuvant
Schuhmacher et al[20]	5-FU, LV, cisplatin	94.4	100	72	95.7	72.7	0.2
	Surgery alone			72		69.9
Adjuvant
Bajetta et al[21]	EAP, 5-FU + LV	91	51	137	73	52	0.87
	Surgery alone			137		48
Chipponi et al[22]	5-FU, cisplatin	80	75	101		39.0	NS
	Surgery alone			104		38.7
Bouché et al[23]	5-FU, cisplatin	80.3	77.9	127	55.9	46.6	0.22
	Surgery alone			133		41.9
Sasako et al[24]	S-1	90.4	45.1	529	100	71.7
	Surgery alone			530		61.1
Bang et al[25]	Capecitabine, oxaliplatin	91	45	520	100	83	0.493
	Surgery alone			515		78
Kang et al[26]	MMC + 5’FDR (MF’) vs	90	43	424	100	66.5	0.33
	MF’ + CDDP			431		65
Di Costanzo et al[27]	PELF	83.8	49.2	130	55	47.6	0.41
	Surgery alone			128		48.7
De Vita et al[28]	ELFE	72	80	112	79	48	0.610
	Surgery alone			113		43.5
Nitti et al[29]	FAMTX or FEMTX	82	61	194	88	43	0.86
	Surgery alone			203
Neri et al[30]	EPI, LV, 5-FU	100	84	69		30 m’s (median)	< 0.01
	Surgery alone			68		18
Perioperative
Cunningham et al[31]	EPI, 5-FU, cisplatin	71	56	250	28	36.3	0.009
	Surgery alone			253		23.0
Ychou et al[32]	5-FU, cisplatin	67	58	113	100	38	0.02
	Surgery alone			111		24

5-FU: 5-fluorouracil; EAP: Etoposide, adriamycin, cisplatin; LV: Leucovorin; MMC: Mitomycin C; 5’ FDR: Doksifluridine; EPI: Epirubicine; FAMTX: Fluorouracil, adriamycin; methtrexate; FEMTX: Fluorouracil, epirubicin; methtrexate; PELF: Cisplatin, epirubicin, leucovorin, 5- fluorouracil; ELFE: Epirubicin, leucovorin, 5-fluorouracil, etoposide; CDDP: Cisplatin; LN: Lymph node.